HIV vaccine trial: which schedule wins?
NCT ID NCT00490074
First seen Apr 25, 2026 · Last updated May 11, 2026 · Updated 2 times
Summary
This study tested two different schedules of an experimental HIV vaccine in 147 healthy adults at low risk for HIV. The goal was to see which schedule produced a stronger immune response and was safer. Volunteers received either three DNA vaccines followed by one booster, or two DNA vaccines followed by two boosters, and were monitored for 72 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, 1011, Switzerland
-
Hôpital Henri Mondor
Créteil, 94010, France
Conditions
Explore the condition pages connected to this study.